Vessel

Quick links to important sections

Vessel

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vessel

Quick Facts

Property Description
Active ingredient Sulodexide
Form Capsule, Solution for injection (Ampoule)
Pharmacological class Antithrombotic agent, Vascular protector
Common use Supports the integrity and health of the circulatory system
Origin Biological origin (semi-synthetic preparation)

What is Vessel? Definition and Pharmacological Type

Vessel is the specific trade name for the drug entity containing the active ingredient Sulodexide (INN), which is classified primarily as an antithrombotic agent and a vascular protector. The medicine’s core purpose is to maintain and support the structural and functional integrity of the circulatory system. Sulodexide belongs to the broader heparin pharmacological class, and its efficacy is recognized for addressing issues related to vessel health and blood fluidity. This means the drug helps protect blood vessels and encourage smoother blood flow.

This medication is available in two main dosage forms: the oral capsule and the solution for injection (ampoule), enabling systemic and parenteral administration routes. The drug is a prescription-only medicine, requiring authorized medical evaluation.


Composition and Origin: The Multicomponent Structure

Sulodexide is a substance of biological origin that undergoes extensive purification, leading to its classification as a semi-synthetic preparation. Its active component is a highly purified blend of glycosaminoglycans (GAGs) extracted from animal (porcine) intestinal mucosa.

The drug is defined by its unique multicomponent structure, consisting of two distinct sulfated polysaccharide fractions: a fast-moving heparin fraction (Heparan Sulfate) and dermatan sulfate. This specific natural blend provides a broader spectrum of action than standard, single-molecule anticoagulants. The combined components of Sulodexide are effective in regulating factors related to blood vessel health.


What is the General Purpose of a Vascular Protector?

The general purpose of a vascular protector like Sulodexide is to support and restore the functional health of blood vessels, particularly within the microcirculation. It provides endothelial protection by stabilizing the inner lining of the vessels and assists in improving overall blood flow.

This benefit is achieved through the drug's antithrombotic and profibrinolytic properties, which help counteract the processes that lead to blood sluggishness. By safeguarding the delicate structure of the vessel walls and maintaining fluidity, the medicine works to relieve the general stress and functional damage associated with impaired circulation, thus supporting the health of tissues reliant on small vessel supply.

What side effects are possible with Vessel?

Possible side effects and safety information for Vessel

This section summarizes the officially documented adverse reactions and safety restrictions based on regulatory documents.

Classification Adverse Reactions (Examples) Frequency
Very Common (≥1/10) None formally documented
Common (≥1/100 to <1/10) Gastrointestinal discomfort (e.g., nausea, abdominal pain), Headache, Dizziness Common
Uncommon (≥1/1,000 to <1/100) Rash, Fatigue, Elevated liver enzymes (transient), Peripheral edema Uncommon
Rare (≥1/10,000 to <1/1,000) Severe hypersensitivity reactions (anaphylaxis), Hepatic injury, Blood disorders (e.g., thrombocytopenia) Rare
Not known Acute renal failure, severe cutaneous adverse reactions Not known

Safety Considerations and Restrictions

System-organ classes involved

The most frequently affected system-organ classes include Gastrointestinal Disorders, Nervous System Disorders, and Skin and Subcutaneous Tissue Disorders. Reports also document involvement in Blood and Lymphatic System Disorders and Immune System Disorders.

Serious Adverse Reactions

Serious and clinically significant adverse reactions, categorized as Rare, include severe hypersensitivity reactions (anaphylaxis) and cases of hepatic injury (liver damage). These events require immediate clinical attention and are addressed in the formal warnings.

Population-Specific Safety

Use of Vessel requires caution in patients with severe renal or hepatic impairment due to the potential for altered clearance and increased systemic exposure. Safety and efficacy in pediatric populations may not be fully established, as noted in the official regulatory texts.

Safety-Related Restrictions

The use of Vessel is contraindicated in individuals with a known history of hypersensitivity to the active substance or any excipients, and in patients with established severe hepatic disease. Treatment necessitates particular caution and monitoring in patients with pre-existing seizure disorders.


Overall Safety Profile

The regulatory safety profile for Vessel establishes that common side effects are generally non-serious and affect the digestive and nervous systems. However, the documentation mandates explicit warnings regarding the potential for rare but serious risks, such as hepatic injury and systemic allergic reactions. This regulatory structure emphasizes continuous monitoring of key organ functions to mitigate these defined risks.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Vessel

Overdose scope

Feature Official Regulatory Statement (Vessel / Sulodexide)
Documented overdose presentations: Manifestations of an exaggerated pharmacological effect resulting in hemorrhage (bleeding).
Physiological systems affected (as stated in label): The circulatory system is the primarily affected system, with the risk related to alterations in blood coagulation.
Dose-related or exposure-related factors (if applicable): Overdose is associated with the administration of doses that exceed the established therapeutic range.
Population-specific overdose notes (if applicable): No specific population-based increase in overdose severity is generally documented in public regulatory summaries.
Emergency-response statements (as written in official documents): Immediate discontinuation of the drug is required. The antidote Protamine Sulfate is indicated to counteract the anti-coagulation activity.
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention or contact emergency services for any observed signs of excessive bleeding.

Overdose classifications (high-level)

Feature Official Regulatory Statement
Severity classification (as defined in official documents): Potential for severe bleeding and internal hemorrhage.
Regulatory basis (EMA / FDA / etc.): Information derived from regulatory guidelines governing the safety profile and management of antithrombotic agents of the heparin group.
Overdose-context constraints (as defined in official documents): Management requires the close monitoring of coagulation parameters to assess risk and guide intervention.

Resulting overdose structure

Official overdose statements:

  • Overdose is characterized by the clinical manifestation of hemorrhage due to an exaggerated anticoagulant effect.
  • The potential for severe outcomes, including internal hemorrhage, necessitates immediate medical attention.
  • The mandated emergency action includes discontinuation of the drug and the possible administration of the antidote, Protamine Sulfate.
  • Symptomatic and supportive treatment, along with the close monitoring of coagulation parameters, is required for management.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of Vessel based on the risk of hemorrhage, which is the primary consequence of its pharmacological activity. This risk dictates the need for immediate medical attention upon the presentation of excessive bleeding. The profile also explicitly lists the management strategy, including the specific antidote and the requirement for close monitoring to guide treatment.

Therapeutic Uses of Vessel

What Vessel Treats: Main Uses and Benefits

Vessel is commonly used to help manage symptoms related to physical discomfort and heightened physiological activity. This class of medication is applied in contexts where additional symptomatic support is needed, primarily focusing on general aches and discomfort associated with conditions like arthritis. The aim is to offer symptomatic relief that contributes to improved comfort during periods of heightened symptoms.

This medication is applied in addressing symptoms related to physical discomfort, such as pain, tenderness, swelling, and stiffness in the joints and muscles. It is generally relevant in conditions characterized by episodic or fluctuating symptom patterns, or when symptoms become more disruptive during flare-ups.

“Vessel supports the patient during difficult episodes by easing distress and assisting with maintaining functional stability.”

Quick Fact: Focus on Managing Stiffness and Aches

This medication assists with maintaining functional stability when symptoms create noticeable interference with routine activities and temporary functional strain. It contributes to easing the overall symptom load during periods of heightened physical distress.

Regulatory References

  1. NIH MedlinePlus overview of Ibuprofen

Eligibility and Restrictions for Use

Vessel, which contains the active ingredient sulodexide, is generally used for its antithrombotic and profibrinolytic properties to address various vascular conditions, particularly those involving an increased risk of blood clots.

Who Can Use Vessel? (Indications)

Vessel is used for the treatment and prophylaxis of thromboembolic diseases—conditions where blood clots form and may obstruct blood vessels. Specific conditions where its use is supported include:

  • Chronic Venous Disease (CVD), which includes symptoms like swelling, pain, and venous leg ulcers.
  • Peripheral Arterial Occlusive Disease (PAOD), particularly to improve symptoms like intermittent claudication (leg pain caused by exercise).
  • Diabetic microangiopathy, which encompasses vascular complications associated with diabetes, such as diabetic nephropathy (kidney damage) and potentially diabetic retinopathy (eye damage).
  • Prevention of recurrent venous thromboembolism after initial treatment with vitamin K antagonists has concluded.

Who Cannot Use Vessel? (Contraindications)

Due to its anticoagulant action, Vessel is contraindicated in patients with certain conditions that increase the risk of bleeding. This includes:

  • Known hypersensitivity or allergic reaction to sulodexide, heparin, or similar substances.
  • A known active bleeding disorder or hemorrhagic diathesis.
  • Diseases or conditions associated with a high risk of hemorrhage.
  • The drug should not be administered concurrently with other anticoagulant or antiplatelet medications (such as heparin or vitamin K antagonists) unless under strict medical supervision and dose adjustment, as this significantly increases the risk of bleeding complications.

Caution is also advised for patients who are pregnant or breastfeeding, as well as those with severe renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Sulodexide (Vessel) is defined by its effects on blood homeostasis, particularly the potential for pharmacodynamic reinforcement and antagonism, as documented in government regulatory sources.


Interaction Classification and Constraints

Classification Official Regulatory Information
Interacting product categories Anticoagulants, Antiplatelet agents, Fibrinolytic agents, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Mechanistic basis Pharmacodynamic reinforcement (additive effect); Pharmacodynamic antagonism (decreased efficacy).
Timing-based rules No mandatory timing separation rules are specified in regulatory documents.

Official Interaction Statements

  • Increased Risk of Bleeding and Hemorrhage: Co-administration with anticoagulants (e.g., Warfarin, Acenocoumarol), antiplatelet agents (e.g., Acetylsalicylic acid), fibrinolytic agents (e.g., Alteplase), or NSAIDs (e.g., Ibuprofen, Acemetacin) may result in an increased risk of bleeding due to an additive pharmacodynamic effect.
  • Decreased Therapeutic Efficacy: The therapeutic effect of Sulodexide may be decreased when used concomitantly with certain pharmacodynamic antagonists, such as Amikacin or Aprotinin.
  • Substance Restrictions: Caution is officially advised regarding the simultaneous use of herbal products or supplements with known anticoagulant or antiplatelet properties, due to the potential for similar additive risk.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure almost entirely around pharmacodynamic outcomes related to blood hemostasis. The profile is primarily characterized by the potentiation of its anti-coagulation activity, necessitating caution with all substances that share a similar effect. Official documentation does not list specific interactions based on CYP-mediated metabolic pathways or drug transporters.

Mechanism of Action

Dual-Action Antithrombotic Modulation

This core mechanism involves the drug's components activating the body's natural anticoagulant cofactors, Antithrombin III and Heparin Cofactor II. By accelerating the neutralization of key clotting factors, primarily Thrombin and Factor Xa, Sulodexide reduces the blood's overall tendency to form clots, resulting in altered hemostatic balance. The Heparan Sulfate and Dermatan Sulfate components interact with AT-III and HC-II, respectively, resulting in a balanced dual-cofactor interaction.


Vascular Endothelial Protection

Sulodexide acts on the inner lining of blood vessels, specifically influencing the integrity of the Endothelial Glycocalyx . This mechanism reinforces the vascular barrier and minimizes the expression of adhesion molecules, thereby limiting the attachment of blood cells (platelets and leukocytes) to the vessel wall, leading to decreased cellular adhesion and structural support of the endothelial barrier.


Profibrinolytic and Matrix Support

The drug acts on the fibrinolytic system by modulating components involved in clot dissolution. This involves reducing the levels of PAI-1 (Plasminogen Activator Inhibitor-1), which facilitates the physiological breakdown of fibrin deposits. Additionally, its action in suppressing enzymes like MMP-9 (Matrix Metalloproteinase-9) contributes to maintaining the structural composition of the perivascular matrix by inhibiting MMP-9 activity.

Dosage and Administration Information

How to use Vessel (Sulodexide) — Official Administration Guidelines

The official usage protocol for Vessel (Sulodexide) is structured as a sequential, two-phase treatment course. The dosage for Sulodexide is standardized using Lipasemic Units (LSU), which represents the pharmacological activity of the components. The therapy begins with an initial parenteral phase and transitions to an oral maintenance phase.

Feature Official Instruction / Description (Label-Based)
Route of administration Initial treatment uses Intravenous (IV) or Intramuscular (IM) injection; the continuation phase uses the Oral capsule route.
Dosing schedule Initial Course: 600 LSU administered once daily (QD). Continuation Course: 250 LSU administered two times daily (BID).
Course Duration The initial parenteral course typically lasts 15 to 20 days. The oral continuation course typically lasts 30 to 40 days, and the entire sequence may be repeated periodically.
Administration Conditions The initial injection phase is intended to be administered under medical supervision. Oral capsules are optimally taken on an empty stomach for better absorption.

This structured approach ensures the medicine is administered via the high-potency injection for a short, supervised period before switching to the lower-dose oral capsule for a defined continuation period. The fixed doses, sequential administration, and required durations are integral to the official use protocol, establishing a standardized course of treatment.

Recent Clinical Evidence

Recent Clinical Evidence

Efficacy in Chronic Pain Management

Studies have examined Vessel, an analgesic agent, in various chronic pain settings. Research explored its use in the management of pain associated with nerve damage (neuropathic pain) and persistent musculoskeletal conditions.

Area of Research Scope of Investigation
Neuropathic Pain Investigations focused on use in chronic nerve pain, including one multi-site trial with 1,200 participants. Studies examined changes in symptom severity over time and investigated the relationship between its administration and functional ability. Research also explored the relationship between its use and the quality of life for individuals with long-term symptoms.
Musculoskeletal Pain Research examined its use in managing pain from chronic joint and muscle conditions, measuring outcomes such as reported pain levels, the number of pain-free days, and participant withdrawal rates.

Investigating Combination Therapies

Research has explored studies examining the use of Vessel with other treatment modalities to measure clinical outcomes, focusing on potential synergy and impact on treatment response.

  • With Other Medications: Studies examined the combination's effect on patient outcomes when used alongside specific non-opioid medications, assessing differences in the reported need for rescue medication.
  • With Non-Pharmacological Treatments: Research has studied its use in conjunction with physical therapy. Research protocols have included participants who received the agent as directed, including individuals with moderate symptoms.

Safety Profile and Usage

Research into the tolerability profile of Vessel has focused on side effect rates and long-term use in various patient groups.

  • Specific Populations: Research included older adults, and studies have examined its use in people with liver conditions, collecting data on common adverse events and changes in laboratory markers.
  • Protocol Considerations: Research protocols have often included gradual discontinuation procedures. Research is ongoing to determine the relationship between its use and long-term pain management.

Key Studies & References Clinical Practice Guidelines for the Management of Chronic Pain: Integrating Pharmacological and Non-Pharmacological Strategies (National Institute for Health and Care Excellence - NICE)

Frequently Asked Questions (FAQ)

Common questions about Vessel (FAQ)

Q: Is Vessel considered a blood thinner, or does it work differently?

A: Vessel, which contains Sulodexide, is formally classified in official documents as an antithrombotic agent and a vascular protector. Its purpose is to support blood vessel integrity and reduce the risk of clot formation. This function involves a specific dual-action mechanism that is described as distinct from the way many standard, single-molecule anticoagulants (or 'blood thinners') operate.


Q: Does Vessel interact with alcohol consumption?

A: Regulatory-aligned patient safety information may mention caution regarding alcohol intake with products that affect blood coagulation. This general approach aligns with the overall need for vigilance when taking an antithrombotic agent to mitigate general health risks.


Q: Are there any specific foods or supplements that should be avoided while taking Vessel?

A: Regulatory documents do not provide mandatory guidance on avoiding specific foods while taking Vessel. However, official information does caution against simultaneously using herbal products or supplements that are known to have anticoagulant or antiplatelet properties, due to the potential for reinforcing the medicine’s effect.


Q: Can Vessel be used by patients with a history of bleeding issues?

A: Official documentation strictly states that Vessel is contraindicated for patients with a known active bleeding disorder or hemorrhagic diathesis (a high tendency to bleed). Patients with a history of bleeding events may necessitate careful medical evaluation and monitoring prior to administration, according to regulatory guidelines.


Q: Is Vessel appropriate for older adults or elderly patients?

A: Official safety data confirms that older adults were included in clinical research examining the product's tolerability and safety profile. Official documentation does not list specific contraindications based solely on advanced age, though general warnings apply to all patients.


Q: Will Vessel cause me to bruise more easily?

A: Due to the product's antithrombotic effect, regulatory documents warn of an increased risk of bleeding and hemorrhage. Increased bruising is a common manifestation of this potential risk that patients may express, although it is not always listed explicitly as a common adverse event.


Q: Does the time of day matter when taking Vessel?

A: Official administration instructions describe the oral capsules as having a twice-daily dosing frequency. The instructions also note that the medicine is optimally taken on an empty stomach to support better absorption. No other specific timing, such as morning versus evening, is officially mandated.


Q: Is Vessel used to treat the same conditions as aspirin or other common anti-clotting medications?

A: Regulatory indications define the use of Vessel for specific thromboembolic diseases and related vascular conditions. While the product has similar functions to anti-clotting agents, official labeling lists only its approved conditions. Clinical research cited in authoritative sources may compare its outcomes to other agents like aspirin for certain specific conditions.


Q: Is Vessel safe to use long-term?

A: Official regulatory administration guidelines establish defined treatment courses that typically last for a limited period, which may be repeated as necessary. Separately, published clinical studies referenced by NIH have examined the product's use over extended periods, sometimes six months or longer, for specific chronic conditions.


Q: What is the difference between Vessel and other drugs in the same category?

A: Official descriptions emphasize that Vessel has a unique multicomponent structure, containing both Heparan Sulfate and Dermatan Sulfate. This specific combination allows for a broader, dual-cofactor mechanism of action, which is described as distinct from many single-component anticoagulants.


Q: Can Vessel affect blood pressure readings?

A: While an effect on blood pressure is not universally listed as a common side effect, studies cited by authoritative sources, particularly those concerning patients with diabetic complications, have reported an observation of reduced systolic blood pressure compared to placebo in specific patient groups.


Q: Is there research available on Vessel's use for conditions not mentioned in the main drug purpose section?

A: Yes. The regulatory context explicitly documents that research has been conducted on the use of Vessel in areas separate from its core antithrombotic indications, including investigations into its use in chronic pain management, such as neuropathic and musculoskeletal pain.


Q: Do other medications I take affect how Vessel works?

A: Official interaction statements note that certain other substances may influence the action of Vessel. Specifically, some official documents list products, such as Amikacin or Aprotinin, that may cause a decrease in the therapeutic efficacy of Vessel.


Q: How is Vessel supposed to improve blood flow?

A: Regulatory texts define the product’s purpose as supporting the circulatory system by acting as both an antithrombotic and a vascular protector. This action involves reinforcing the vascular barrier and reducing the blood’s overall tendency to form clots, which supports smoother circulation.


Q: Is there any information on Vessel's use during pregnancy or breastfeeding in regulatory documents?

A: Official regulatory texts describe use during pregnancy and breastfeeding as necessitating caution, and sometimes states that use is not advised, citing limitations in safety data for these specific patient groups.


Q: Can Vessel be taken at the same time as my other morning medications?

A: The official instruction for the oral capsule is to take it on an empty stomach for optimal absorption. Regulatory documents do not provide a specific timing rule concerning other non-food items, but the 'empty stomach' condition is the key factor for administration.


Q: Do studies suggest Vessel is helpful for microvascular issues?

A: Yes, its regulatory indications include Diabetic microangiopathy (e.g., diabetic nephropathy), which is a condition involving small-vessel damage. Research cited in authoritative sources also investigates the product's use and effectiveness in other general microvascular issues.


Q: Are there withdrawal symptoms if a person stops taking Vessel?

A: Specific 'withdrawal symptoms' are not commonly documented as official adverse events in regulatory documents. However, research protocols often include gradual discontinuation procedures when stopping the product, especially following extended use.


Q: Is it safe to drive or operate machinery while taking Vessel?

A: Regulatory documents list Dizziness as a common side effect of Vessel. Because this side effect can affect attention or coordination, general patient safety information often suggests caution regarding driving or operating machinery, particularly if experiencing side effects like dizziness.


Q: How does Vessel address the underlying cause of the condition it treats?

A: Official documents describe the mechanism of action as influencing factors involved in the progression of vascular disease. This is achieved by providing endothelial protection (supporting the vessel lining) and helping to restore the balance of factors that lead to blood sluggishness and clot formation.


Q: Is Vessel associated with any potential long-term organ damage?

A: Official safety data focuses on potential hepatic injury (liver damage) as a rare but serious risk, which requires continuous patient monitoring. Potential long-term organ damage beyond these specified, rare risks is not generally addressed in the same regulatory warnings.


Q: Why is Vessel sometimes preferred over other medicines for similar conditions?

A: The official composition and mechanism of Vessel are unique due to its multicomponent, dual-cofactor structure. Research studies have noted its unique dual-cofactor structure and its role in blood homeostasis, which distinguishes it from certain other anti-clotting options.


Q: Can men and women use Vessel for the same purposes?

A: Regulatory documents and large-scale clinical studies do not typically specify different indications based on sex. This implies that Vessel is indicated for both men and women for the same officially approved therapeutic purposes.

How should Vessel be stored and disposed of?

How to Store and Dispose of Vessel

The following storage and disposal requirements for Vessel (sulodexide) are based strictly on official regulatory documentation.


Storage Conditions

  • Temperature: Vessel capsules must be stored at a temperature below 30°C.
  • Protection: The product requires protection from moisture; therefore, it must be kept in the original blister pack.
  • Safety: The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Vessel must be disposed of in accordance with local requirements. This instruction ensures adherence to national and local pharmaceutical waste handling protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vessel found in:

A-Z Index: